IL-12 targeting could open pathways for new Alzheimer’s treatments

Researchers from Charité – Universitätsmedizin Berlin and the Max Delbrück Center have detailed the precise mechanism through which the inflammatory signaling molecule IL-12 contributes to Alzheimer’s disease.